Related Experiment Videos
Somatostatin and cancer
1Department of Endocrinology and Metabolism, Cornell University Medical College, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
The potential role of somatostatin (SRIF) in the diagnosis and treatment of nonendocrine human cancers is reviewed. There have been many reports of the growth-inhibitory activity of SRIF on normal and transformed cells in vitro. Many processes involved in malignant tumor growth depend on autocrine growth mechanisms, and somatostatin receptors (ssts) are present on many human cancers. It is possible that mutations in ssts result in a loss of check on proliferation in cancer cells. SRIF analogs may have a number of roles in clinical oncology. Use of radiolabeled tracers enables imaging of tumors bearing ssts; newer agents may enable positron emission tomography (PET) analyses or may be used to deliver lethal radiation doses to cells bearing a unique subset of sst. Although the ability of SRIF and its analogs to inhibit cellular proliferation has been shown in vitro, it has yet to be demonstrated in humans with cancer. Clinical improvements seen with SRIF or its analogs in cancer patients may be related to indirect effects, such as pain relief, reduction of gastrointestinal side effects of chemotherapeutic agents, effects on local production of growth factors, and inhibition of tumoral angiogenesis. Thus, with regard to their potential therapeutic role, SRIF analogs are likely to be used only in conjunction with other approaches, such as radiation, immunotherapy, chemotherapy, and growth factor modulation. Further research into the fundamental functions of each of the ssts and the intracellular actions of SRIF analogs will be needed to assess the potential usefulness of the latter in slowing the progression of human cancers.
Insights
Somatostatin (SRIF) shows potential in nonendocrine cancer diagnosis and treatment by inhibiting tumor growth. SRIF analogs may aid in imaging and therapy, but further research is needed to confirm efficacy in human cancers.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Somatostatin (SRIF) exhibits growth-inhibitory effects on normal and cancerous cells in vitro.
- Somatostatin receptors (ssts) are expressed on numerous human cancers, suggesting a role in regulating proliferation.
Purpose of the Study:
- To review the potential applications of somatostatin (SRIF) and its analogs in the diagnosis and treatment of nonendocrine human cancers.
- To explore the mechanisms and clinical utility of SRIF in oncology.
Main Methods:
- Review of existing literature on SRIF, somatostatin receptors (ssts), and their role in cancer.
- Discussion of diagnostic imaging techniques using radiolabeled SRIF analogs (e.g., PET).
- Exploration of therapeutic strategies involving SRIF analogs, including direct and indirect effects.
Main Results:
- SRIF and its analogs demonstrate in vitro growth inhibition of cancer cells.
- SRIF analogs can be used for tumor imaging via radiolabeled tracers and potentially for targeted radiation delivery.
- Clinical benefits observed in cancer patients may stem from indirect effects like pain relief and reduced chemotherapy side effects.
Conclusions:
- SRIF analogs hold promise for cancer diagnosis and as adjuncts in therapy, particularly for imaging and potentially delivering targeted radiation.
- Further investigation into sst subtypes and intracellular SRIF signaling is crucial for optimizing therapeutic strategies.
- SRIF analogs are likely to be most effective when used in combination with established cancer treatments.